# Bioequivalence Study of WP205 in Healthy Participants

> **NCT07281872** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Wanbangde Pharmaceutical Group Co., LTD** · enrollment: 20 (estimated)

## Conditions studied

- Therapeutic Equivalency, Healthy

## Interventions

- **DRUG:** Methylconalamin Injection(WP205)
- **DRUG:** Methylconalamin for Injection

## Key facts

- **NCT ID:** NCT07281872
- **Lead sponsor:** Wanbangde Pharmaceutical Group Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-29
- **Primary completion:** 2025-11-06
- **Final completion:** 2028-11-25
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07281872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07281872, "Bioequivalence Study of WP205 in Healthy Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07281872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*